COVID-19 mRNA vaccine targeting S-RBD (RNACure Biopharma)

1. De novo design of covalent bonding peptides for target proteinhLife | 周小红/王奇慧等合作开发两步法从头设计的共价键合肽抑制剂通讯作者：周小红、王奇慧、Lip Ket Chin本研究展示了共价抑制剂在抗病毒药物研发中的潜力，并且将计算设计和实验验证相结合，加速了新药物的开发，此外，通过引入非天然氨基酸并同时改进分子动力学预测力场，也为蛋白质工程和药物设计提供了新的策略。引用：Zhou X, Zhu Q, Zheng A, et al. De novo design of covalent bonding peptides for target protein. hLife 2024; 2: 641–652.2. Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platformshLife | 从灭活苗到mRNA疫苗：不同技术路线如何塑造免疫记忆？通讯作者：华兆林、侯百东本研究证实疫苗的技术路线差异对免疫应答和免疫记忆生成的效果会产生明显的影响。深入探索不同疫苗的免疫机制，不仅能揭示现有疫苗在免疫保护持久性上的优势和不足，还将有助于理解不同疫苗在提高免疫保护持久性、应对免疫逃逸等方面的潜力，进而为开发更具长效保护效力且广谱的新型疫苗提供科学依据，推动疫苗的高水平发展。引用：Guo C, Chai X, Baerlike M, et al. Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms. hLife 2024; 2: 625–640.3. Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasionhLife | 鼻黏膜 sIgA 抗体具更强广谱中和能力，且更不容易被奥密克戎变异株逃逸通讯作者：李锋、陈凌本研究发现鼻黏膜 sIgA 比血清抗体具有更强且更广谱的中和活性，凸显了上呼吸道黏膜 sIgA 在预防新冠病毒感染方面的重要作用，也为设计能有效诱导上呼吸道产生sIgA的鼻喷疫苗提供了依据。引用：Chen S, Zhang Z, Wang Q, et al. Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasion. hLife 2024; 2: 488–491.4. Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccinehLife | 新冠疫苗随机临床研究揭示XBB.1.5双价疫苗的优效免疫原性通讯作者：周太成、游顶云、韦嘉、张子杰本研究进行了一项随机、单盲临床试验，头对头比较了含有Omicron XBB.1.5的双价mRNA疫苗（RQ3027）、含有BA.2/BA.5的双价mRNA疫苗（RQ3025），以及其前身——含有Alpha/Beta变异株的单价mRNA疫苗（RQ3013）的安全性、免疫原性和初步效力。引用：Yu X, Yang W, Li W, et al. Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine. hLife 2024; 2: 113–125. 5. Safety and immunogenicity of COVID-19 vaccine ZF2001 in Chinese aged 60 years and olderhLife | 新冠重组亚单位疫苗ZF2001 在中国老年人群中的安全性和免疫原性研究通讯作者：胡忠玉、钟再新、丁帆、李燕本文旨在揭示疫苗ZF2001在老年人群中的安全性、耐受性、免疫原性和持久性，以及对奥密克戎变异株的有效性。引用：Gao L, Yang H, He P, et al. Safety and immunogenicity of COVID-19 vaccine ZF2001 in Chinese aged 60 years and older. hLife 2024; 2: 257–261.6. Developing next-generation tuberculosis vaccines based on pathogen–host interactions: Towards a holistic perspectivehLife | 着眼整体视角：基于病原-宿主互作研发下一代结核病疫苗通讯作者：刘翠华本文系统总结了结核病疫苗研发的困境和挑战，阐述了结核病致病过程中结核分枝杆菌与宿主相互作用的研究进展，并进一步探讨了基于病原-宿主相互作用的新一代高效、低毒、持久的结核病疫苗研发新策略。引用：Lei Z, Wang J, Liu CH. Developing next-generation tuberculosis vaccines based on pathogen–host interactions: Towards a holistic perspective. hLife 2025; 3: 164–171.7. High-resolution crystal structure of human coronavirus HKU1 receptor binding domain bound to TMPRSS2 receptor通讯作者：陈蓉、徐颖、张水军Coronaviruses pose serious threats to global public health, and Human coronavirus HKU1 (HCoV-HKU1) could also result in lower respiratory tract infections with more serious consequences. This study determined the crystal structure of the viral receptor binding domain (RBD) complexed with human TMPRSS2, revealing that the structure of receptor binding HKU1A RBD is highly similar to that of HKU1A RBD in its apo form, except for the β10-β11 strands. The researchers also noted the plasticity and complexity of receptor binding by HCoVHKU1, as the RBD undergoes significant rotation compared to other complex structures. Furthermore, they observed that the inactive form of TMPRSS2, carrying an R255Q mutation, allows HKU1 infection but induces significantly less cell-cell fusion. This study provides the structural basis for the specificity of receptor binding by HCoV-HKU1 and may inform the development of vaccines and antivirals agains.引用：Wang W, Guan J, Ren M, et al. High-resolution crystal structure of human coronavirus HKU1 receptor binding domain bound to TMPRSS2 receptor. hLife 2024; 2: 653–657.8. Discovering broader antiviral strategies: Role of interferon-induced transmembrane proteins in virus infectionhLife | IFITM蛋白家族：广谱抗病毒机制探索通讯作者：曾木圣、孙聪本文从病毒感染与宿主免疫机制的角度点评了Yinggui Yang等发表在Nature Microbiology的文章 “Interferon-induced transmembrane protein-1 competitively blocks Ephrin receptor A2-mediated Epstein–Barr virus entry into epithelial cells”，结合以往的相关研究，总结了IFITM蛋白家族的广谱抗病毒机制，并展望其在抗病毒药物和疫苗研发方面的应用潜力。引用：Jiang ZY, Xie C, Wu PH, et al. Discovering broader antiviral strategies: Role of interferon-induced transmembrane proteins in virus infection. hLife 2024; 2: 377–379.9. Why is the Omicron main protease of SARS-CoV-2 less stable than its wild-type counterpart? A crystallographic, biophysical, and theoretical study通讯作者：Jana Shen、Rolf HilgenfeldThe Nsp5 main protease (Mpro) of the Omicron virus is characterized by a single dominantmutation, P132H. Here we determined the X-ray crystal structures of the P132H mutant (or O-Mpro)as a free enzyme and in complex with the Mpro inhibitor, the alpha-ketoamide 13b-K, and we conducted enzymological, biophysical, as well as theoretical studies to characterize the O-Mpro. We found that O-Mpro has a similar overall structure and binding with 13b-K; however, it displays lower enzymatic activity and lower thermal stability compared to the WT-Mpro(with “WT” referring to the prototype strain). Intriguingly, the imidazole ring of His132 and the carboxylate plane of Glu240 are in a stacked configuration in the X-ray structures determined here. Empirical folding free energy calculations suggest that the O-Mpro dimer is destabilized relative to the WT-Mpro due to less favorable van der Waals interactions and backbone conformations in the individual protomers. All-atom continuous constant-pH molecular dynamics (MD) simulations reveal that His132 and Glu240 display coupled titration. At pH 7, His132 is predominantly neutral and in a stacked configuration with respect to Glu240 which is charged. In order to examine whether the Omicron mutation eases the emergence of further Mpromutations, we also analyzed the P132H+T169S double mutant, which is characteristic of the BA.1.1.2 lineage. However, we found little evidence of a correlation between the two mutation sites.引用：Ibrahim M, Sun X, Martins de Oliveira V, et al. Why is the Omicron main protease of SARS-CoV-2 less stable than its wild-type counterpart? A crystallographic, biophysical, and theoretical study. hLife 2024; 2: 419–433.10. Modeling viral evolution: A novel SIRSVIDE framework with application to SARS-CoV-2 dynamicshLife | 陆剑研究团队研发SIRSVIDE模型解析病毒进化动态通讯作者：陆剑本研究研发了SIRSVIDE（Susceptible-Infected-Recovered-Susceptible-Variation-Immune Decay-Immune Escape ）的新型计算模型，用于模拟病毒种群的传播和进化动态。引用：Jin K, Tang X, Qian Z, et al. Modeling viral evolution: A novel SIRSVIDE framework with application to SARS-CoV-2 dynamics. hLife 2024; 2: 227–245.11. Impact of COVID-19-related nonpharmaceutical interventions on diarrheal diseases and zoonotic SalmonellahLife | COVID-19相关非药物干预措施对急性腹泻和人畜共患沙门菌的影响通讯作者：乐敏本研究对比了浙江省杭州市急性腹泻疾病的发病情况，并通过生物信息学方法解析了NTS的基因组数据。研究发现，与COVID-19相关的非药物干预措施有效降低了急性腹泻的发病率，但NTS的感染情况出现了意外的增加。总体上，NTS的耐药性、耐消毒能力和毒力能力有所降低，人畜共患传播的规模也减小，这暗示着NTS可能通过其他潜在途径感染人类。尽管多项非药物干预措施主要用于应对新冠大流行，但它对其他传染病和非传染病的研究仍值得进一步关注。引用：Huang L, Zhou H, Chen J, et al. Impact of COVID-19-related nonpharmaceutical interventions on diarrheal diseases and zoonotic Salmonella. hLife 2024; 2: 246–256.12. A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motifhLife | 深圳大学张素平研究团队获得一种靶向新冠病毒关键表位的中和抗体通讯作者：王岚峰、林正红、张素平本研究揭示了SARS-CoV-2 S2亚基HR2基序的上游保守区域潜在的利用价值，有利于针对冠状病毒开发广谱的中和抗体及疫苗。引用：Su H, Zhang J, Yi Z, et al. A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif. hLife 2024; 2: 126–140. 13. 778th Xiangshan Science Conference convenes experts to explore breakthroughs in lung and respiratory mucosal immunity通讯作者：王硕The 778th Xiangshan Science Conference, themed “Regional Immunity in the Lung and Respiratory Tract: Challenges and Opportunities”, convened in Beijing on April 8–9, 2025. Co-chaired by four leading scientists—Professor George Fu Gao (Institute of Microbiology, Chinese Academy of Sciences), Professor Chen Dong (Westlake University School of Medicine), Professor Zhigang Tian (University of Science and Technology of China), and Professor Fusheng Wang (The Fifth Medical Center of Chinese PLA General Hospital)—the conference assembled over 50 multidisciplinary scholars to tackle pressing challenges in mucosal immunology. This gathering aimed to advance innovative strategies for the prevention, diagnosis, and treatment of respiratory diseases.引用：Yan Q, Wang S, Shi Y. 778th Xiangshan Science Conference convenes experts to explore breakthroughs in lung and respiratory mucosal immunity. hLife 2025; https://doi.org/10.1016/j.hlife.2025.04.006.14. Systemic profiling of immune responses in healthy adults vaccinated with an RBD-targeting COVID-19 mRNA vaccine通讯作者：赵慧、秦成峰Highlights• ARCoV vaccination elicits increased expression of C-X-C motif chemokine ligand 10 (CXCL10) and interferon-gamma (IFN-γ).• Single-cell sequencing shows expansion of interferon-activated and proliferating T cell subsets after immunization.• ARCoV induces expansion of T cell receptor (TCR) clones in effector T cells and KIR+ natural killer (NK)-like cells.引用：Zhou C, Sun M, Huang X, et al. Systemic profiling of immune responses in healthy adults vaccinated with an RBD-targeting COVID-19 mRNA vaccine. hLife 2025; https://doi.org/10.1016/j.hlife.2025.04.008.15. Selection and engineering of broad-spectrum antiviral affibody peptides against SARS-CoV-2 variants通讯作者：Christopher John Hipolito、齐建勋、施一In summary, we successfully identified ZSpike:2, a broad-spectrum antiviral affibody targeting SARS-CoV-2 S protein, through mRNA display technology. To improve its neutralizing potency, ZSpike:2 was structurally optimized using three multimerization engineering strategies: a (GGGGS)3-linked homodimer, (ZSpike:2)2 fused with the Fc region of IgG1, and a self-assembled ferritin nanoparticle displaying the (ZSpike:2)2-Fc. The nanoparticle-conjugated construct, (ZSpike:2)2-Fc-ferritin, exhibited broad-spectrum neutralizing activity against all tested SARS-CoV-2 variants, indicating that it has acquired novel neutralization mechanism compared with the (ZSpike:2)2-Fc. We propose that this modification allows (ZSpike:2)2-Fc to assemble into multimeric structures, enhancing its binding avidity to the S protein. Additionally, when (ZSpike:2)2-Fc-ferritin specifically binds to the S protein, the increasing size of (ZSpike:2)2-Fc-ferritin could result in steric hindrance and further block interactions between S protein and ACE2. Moreover, the increasing size of (ZSpike:2)2-Fc-ferritin likely contributes to its broad-spectrum activity by conferring an alternative functional mechanism. This modification strategy is not only applicable to ZSpike:2 but can also be extended to other antiviral protein-binder agents, such as monobodies and nanobodies. Furthermore, the approach of conjugating different antiviral agents with nanoparticles holds promise for developing novel broad-spectrum antiviral drugs. Future studies will assess the in vivo efficacy of (ZSpike:2)2-Fc-ferritin and explore its underlying antiviral mechanisms.引用：Yang J, Wang M, Chen Z, et al. Selection and engineering of broad-spectrum antiviral affibody peptides against SARS-CoV-2 variants. hLife 2025; https://doi.org/10.1016/j.hlife.2025.04.010.16. Enabling the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants including KP.2中科院高福院士团队开发BAADesign：赋能埃特司韦单抗破解新冠Omicron通讯作者：杨梦苏、高福本研究提出了一种基于骨架和序列设计的广谱亲和力成熟抗体开发策略，称为 BAADesign。BAADesign为恢复失效抗体活性提供了全新的思路。通过骨架与序列设计相结合，这一策略赋能了埃特司韦单抗，使其重新获得对Omicron子代变异株的中和能力，也为其他抗体药物的改造提供了范例。未来，这一方法有望为应对新冠病毒及其他快速变异的病原体提供强有力的技术支持。引用：Su C, He J, Xie Y, et al. Enabling the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants including KP.2. hLife 2025; 3: 132–145.17. H3N2 influenza virus characteristics in China (2019–2022): Genetic, antigenic, and infection dynamics during the COVID-19 pandemic中科院微生物所毕玉海团队在季节性流感病毒研究上取得进展通讯作者：张洪春、毕玉海由于流感病毒变异迅速，传统灭活疫苗需要频繁更换疫苗毒株才能维持良好的保护效果。针对这一挑战，基于流感疫苗现有鸡胚生产线，团队研发了甲型流感病毒通用型冷适应疫苗骨架毒株（专利已授权），填补了我国没有自主知识产权的冷适应季节性甲型流感疫苗骨架毒株的空白；基于该疫苗通用骨架，本文针对预警的H2N2、H5N1等风险病毒开展研究；相关研究为突发新发流感疫苗毒株快速构建和鼻喷疫苗的研制提供了科技支撑。引用：Li J, Huan Y, Xia Q, et al. H3N2 influenza virus characteristics in China (2019-2022): Genetic, antigenic, and infection dynamics during the COVID-19 pandemic. hLife 2025; 3: 146–158.18. Palmitic acid esters of hydroxy stearic acid suppresses SARS-CoV-2 infection through inhibiting the non-canonical inflammasome通讯作者：夏朋延 We found that PAHSA can inhibit the immune response caused by SARS-CoV-2. PAHSA enters the cell cytosol and binds to caspase-11, preventing the binding of caspase-11 to LPS, thereby inhibiting the activation of non-canonical inflammasomes and ultimately reducing the serum levels of inflammatory cytokines caused by SARS-CoV-2 infection. The regulation of LPS in cells is currently at the forefront of research. Our previous study has shown that ATGL can bind to LPS and specifically degrade the lipid chains of LPS. This prompted us to consider whether ATGL-synthesized PAHSA also plays a role in non-canonical inflammasome. PAHSA has branched lipid chains similar to the lipid A portion of LPS, which may be the reason for binding to caspase-11. However, the structural basis of PAHSA binding to caspase-11 remains to be clarified, and whether other FAHFAs have the same role needs to be further explored. It is now recognized that hyperinflammation caused by inflammasome plays an important role in the pathophysiology of COVID-19 patients. Most of the previous studies focused on SARS-CoV-2 activating of NLRP3 canonical inflammasome. However, we found that inhibiting caspase-11 in immune cells can also alleviate the symptoms of SARS-CoV-2 infection. This suggests that overactivation of non-canonical pathways may also be an important driver of COVID-19 pathogenesis, which will provide new guidance for future diagnosis and treatment of COVID-19.引用：Kong C, Li Y, Qian Y, et al. Palmitic acid esters of hydroxy stearic acid suppresses SARS-CoV-2 infection through inhibiting the non canonical inflammasome. hLife 2025; https://doi.org/10.1016/j.hlife.2025.01.005.19. Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settingshLife | 广州医科大学赵金存/王延群研究团队证实黏膜疫苗抵抗JN.1效力不足六个月通讯作者：王延群、田新贵、朱爱如、张璐、赵金存本研究系统阐明了Ad5-XBB.1.5黏膜疫苗接种后6个月内上呼吸道黏膜免疫的动态变化特征。研究发现，鼻腔IgA抗体水平随着接种时间延长而显著降低，这可能是黏膜疫苗无法提供长期鼻腔保护的关键因素。这些结果提示，面对快速进化的新冠病毒变异株，可能需要通过定期加强免疫来维持有效的黏膜保护。引用：Wang Y, Wei P, Zhang J, et al. Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings. hLife 2025; https://doi.org/10.1016/j.hlife.2025.05.001.20. Addressing COVID-19 vaccination hesitancy through community engagement and integration with primary health care services in Wakiso district, Uganda通讯作者：David MusokeAfter the discovery and approval of coronavirus disease 2019 (COVID-19) vaccines, the World Health Organization (WHO) set global vaccination coverage targets to achieve herd immunity, aiming to vaccinate at least 70% of the global population. However, the availability of COVID-19 vaccination services in Africa was delayed compared to other regions, leading to lower uptake during the initial stages of the pandemic, hence leaving a considerable portion of the population unvaccinated . Despite numerous efforts of the Ministry of Health in Uganda to control COVID-19, gaps remained in addressing vaccine hesitancy, particularly in urban settings. A package of interventions was therefore implemented to increase the uptake and demand for COVID-19 vaccination services, as well as to support the integration of COVID-19 vaccination into routine primary health care (PHC) services.引用：Musoke D, Masengere P, Ssembuusi A, et al. Addressing COVID-19 vaccination hesitancy through community engagement and integration with primary health care services in Wakiso district, Uganda. hLife 2025; https://doi.org/10.1016/j.hlife.2025.05.012.21. Mucosal vaccine development for respiratory viral infections通讯作者：林逸凡、傅阳心、彭华Highlights• Very few mucosal vaccines for respiratory viral infectious have been approved, and their efficacy is limited.• The development of mucosal vaccines needs thorough investigation of the respiratory tract mucosa microenvironment.• Mucosal adjuvants and delivery systems are critical strategies to enhance the immunogenicity of mucosal vaccines.• Establishing a clinical standardized evaluation system for mucosal vaccines is urgently needed.引用：Lin Y, Hu Z, Fu YX, et al. Mucosal vaccine development for respiratory viral infections. hLife 2024; 2: 50–63.22. T cell cross-reactivity in autoimmune-like hepatitis triggered by COVID-19hLife | 不明原因儿童严重急性肝炎的新假说——新冠超抗原介导的T细胞交叉反应通讯作者：李贵登、王健伟本研究通过干湿结合的方式鉴定得到了在新冠病人中富集并交叉识别自身抗原ABCD3的CoV-TCR。尽管CoV-TCR并不识别之前报道的 SARS-CoV-2抗原肽TTDPSFLGRY，但它依旧有可能识别源自SARS-CoV-2的其他尚未鉴定或报道的抗原肽。此外，他们提出具有相同CDR3β序列CASSLGQAYEQYF的T细胞克隆的扩增也可能归因于COVID-19患者中EBV 的重新激活。以上研究表明，新冠感染介导的交叉反应性T细胞的扩增可能是自身免疫样肝炎（包括病因不明的小儿肝炎）的原因之一，未来需要更全面的研究来探索并验证这一可能性。引用：Liu Y, Wang Y, Peng Z, et al. T cell cross-reactivity in autoimmune-like hepatitis triggered by COVID-19. hLife 2023; 1: 57–61.23. Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide通讯作者：王奇慧HY3000, which has shown significant inhibitory activities against SARS-CoV-2 and all tested variants, including XBB.1.5/XBB.1.9.1/XBB.1.9.2, and has completed Phase II clinical trials in China. HY3000 peptide exhibited comparable inhibitory potencies against EG.5 and EG.5.1, with half-maximal effective concentration (EC50) values of ~50 nM, and also displayed similar inhibitory activities against XBB.1.16, FL.1.5.1, and FY.3 strains. Notably, HY3000 showed slightly higher inhibitory activity against BA.2.86, with an EC50 value of 28.3 nM. HY3000 also potently inhibited live EG.5.1 strain, with an EC50 of 8.8 nM. These results suggest that the HY3000 peptide fusion inhibitor has a potential broad-spectrum antiviral effect against current and future SARS-CoV-2 variants and sub-variants.引用：Wu L, Zheng A, Tang Y, et al. Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide. hLife 2024; 2: 43–46.24. A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoproteinhLife | 高福院士等研究团队获得一种靶向呼吸道合胞病毒保守表位的保护性单克隆抗体通讯作者：谢正德、邬征、高福本研究从康复儿童的体内分离到了两个针对RSV融合蛋白（F）的中和性单克隆抗体。其中1个抗体RV11显示了很高的中和活性，能中和A和B两种基因型的RSV，活性较帕利珠单抗大幅提高。小鼠攻毒试验显示，预防性注射RV11能够保护RSV对肺部的感染，其体内保护活性相较于帕利珠单抗提高了约6.3倍。晶体结构解析揭示这个抗体结合在F蛋白融合前构象的表位，横跨IV和V号位点。该表位在A和B基因型RSV中都非常保守，使得RV11不易于被病毒所逃逸，有利于临床使用。引用：Dai L, Song J, Xu L, et al. A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein. hLife 2023; 1: 12–25.25. Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals王林发团队：新冠病毒原始株与Omicron血清型不同！SARS相关毒株可分为三个血清型通讯作者：Chee Wah Tan、王林发本研究首次从初次感染中恢复的人类血清进行血清型分析研究。研究结果表明，在针对SARS-CoV-1、Ancestral SARS-CoV-2和SARS-CoV-2 Omicron亚变种进行的三向测试中，没有显著的交叉中和作用。这些数据支持将当前已知的感染人类的SARS相关冠状病毒分为三个明确的血清型。引用：Tan CW, Zhu F, Chia WN, et al. Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals. hLife 2023; 1: 26–34.26. Mouse model for pangolin-origin coronavirus GX/P2V/2017 infection and cross-protection from COVID-19 ZF2001 subunit vaccinehLife | 基于RBD的冠状病毒疫苗可作为开发广谱冠状病毒疫苗的候选通讯作者：高玉伟、曹务春、王奇慧、高福本研究探讨了鼠作为庭院动物传播穿山甲来源冠状病毒的可能性，以及基于冠状病毒刺突蛋白受体结合域（RBD）设计的疫苗作为广谱冠状病毒疫苗的潜质。引用：Qu X, Jia Y, Jia N, et al. Mouse model for pangolin-origin coronavirus GX/P2V/2017 infection and cross-protection from COVID-19 ZF2001 subunit vaccine. hLife 2023; 1: 35–43.27. Lycorine derivative effectively inhibits the replication of coronaviruses both in vitro and in vivo通讯作者：殷利眷、杨扬、王春花Highlights• Lycorine derivatives, including Ly-8, were designed and synthesized to reduce cytotoxicity in anti-coronavirus experiments.• Ly-8 inhibits various coronaviruses, including severe acute respiratory syndrome coronavirus 2, in vitro.• Ly-8 did not result in any drug-resistant mutant viruses during long-term in vitro passages.引用：Shen L, Zhao J, Xia Y, et al. Lycorine derivative effectively inhibits the replication of coronaviruses both in vitro and in vivo. hLife 2024; 2: 75–87.期刊简介hLife 由高福院士、董晨院士和Jules A. Hoffmann教授（2011诺奖获得者）领衔，是中国科学院微生物研究所主办，中国生物工程学会，浙江大学陈廷骅大健康学院，西湖大学医学院，上海市免疫治疗创新研究院和广州霍夫曼免疫研究所联合支持，与国际出版商爱思唯尔合作的健康科学领域综合性英文期刊。hLife 聚焦健康科学领域的前沿进展，旨在促进基础研究与临床应用的融合发展。期刊发表与医学相关各研究领域最新成果，学科领域包括（但不限于）病原生物学、流行病学、生理学、免疫学、结构生物学、疾病监测、肿瘤、药物、疫苗和健康政策等。hLife是一本金色开放获取期刊，月刊出版；2022年成功入选“中国科技期刊卓越行动计划高起点新刊”；2023年11月正式创刊；2024年5月被DOAJ收录；2024年8月被Scopus收录；2024年10月入选“首都科技期刊卓越行动计划——重点英文科技期刊支持项目”；2025年6月入选北京市科委“2025年度支持高水平国际科技期刊建设-强刊提升”项目；2025年8月入选中国科学引文数据库（CSCD）核心库。hLife实行高标准与高效率并重的同行评审机制：投稿至给出“是否送审”决定⏰1天投稿至给出“首轮审稿”决定⏰28天投稿至给出“是否录用”决定⏰61天2026年前hLife接收的稿件免收文章处理费（APC）。https://www.sciencedirect.com/journal/hlife